Press release - 29 May 2023 17:18

QureTech Bio Appoints Three New Board Members to Strengthen Drug and Business Development

QureTech Bio AB (QTB), a pharmaceutical development company originating from Umeå University, proudly announces the appointment of three new board members at its Annual General Meeting held on May 25, 2023. This strategic move is aimed at further enhancing QTB's drug and business development.

The newly appointed board members are:

Yijing Sun Hultgren
Yijing has over a decade of experience in finance. In her most recent role, she ran $350mn as a portfolio manager for Millennium, a US hedge fund with $58bn assets under management. Her background is in public equity investing and investment banking. Yijing graduated from Harvard University with a degree in Math and Economics.

Lennart Hansson
Lennart is former head of Life Science Investments at Industrifonden, one of Sweden’s largest venture funds. Previously he has more than 25 years’ experience in the pharma and biotech industry in executive positions at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB and BioVitrum AB and as CEO for Arexis AB. He has a PhD in Genetics from Umeå University.
Other current assignments: Hansson is chairman of the board of Cinclus Pharma Holding AB, Sixera Pharma AB and Ignitus AB, as well as board member of Index Pharamceuticals AB and Medivir AB.

Ulf Björklund
Ulf has more than 35 years of experience from the pharmaceutical industry from research, development and marketing of pharmaceuticals to diagnostics. Previous engagements include CEO of Aprea in oncology and CEO of OxyPharma in autoimmune diseases. Prior to that, he held several senior positions at Pharmacia in clinical research covering many therapeutic areas. Ulf Björklund has additional experience in organization partner collaborations, financing and communication with regulatory authorities in Europe and the USA.
Ulf is currently chairman of the board of Lipum AB and Stayble Therapeutics AB, CEO at UB-consulting AB, CMO at Redwood Pharma AB. Ulf has a Pharmacy degree at Uppsala University.

Contact
Helén Fält, CEO
E-mail: helen.falt@quretech.com
Mobil: +46 70 388 5025
Web: www.quretech.com

Topics

Contacts

Tomas Ruuth

Press contact Head of PR & Communications PR & Communications tomas.ruuth@ubi.se 072-4024697 www.ubi.se

Related media Download images for media use

Ulf Björklund
License: Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
Copyright: Quretech Bio
File format: .jpg
Size: 968 x 1184, 189 KB

Lennart Hansson
License: Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
Copyright: Quretech Bio
File format: .jpg
Size: 2832 x 4104, 988 KB

Yijing Sun Hultgren
License: Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
By: Yijing Sun Hultgren
Copyright: Quretech Bio
File format: .jpg
Size: 541 x 858, 87.5 KB

Namnlös design
License: Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format: .png
Size: 5760 x 3240, 13.7 MB

QureTech Bio receives excellent support for development of new antibiotics

Umeå-based QureTech Bio AB receives support from the Swedish Research Council's major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics.

New at QureTech Bio: Annica Rönnbäck, Mari Bonde and Souvik Sarkar.

16 April 2021 08:04

QureTech Bio expands workforce following major investment

Umeå-based pharmaceutical development company QureTech Bio is hiring more people as it intensifies its work to combat antibiotic resistance. “We recently received a major investment which has created long-term security in the company. With more people in place, we can now really push on and look to the future”, says Helén Fält, who was recently appointed the new CEO of QureTech Bio.

Helén Fält and Fredrik Almqvist, QureTech Bio.

21 January 2021 10:01

QureTech Bio Looks to the Future With Appointment of New CEO

Umeå-based biotech company QureTech Bio has appointed Helén Fält as its new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders. “We have recently secured significant new investment and so it feels like the perfect time for Helén to come in and develop our business even further,” says Fredrik Almqvist.